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 Abstract 
 
Purpose  To investigate the development of polypoidal lesions using indocyanine 
green angiography (IA) in eyes with typical age-related macular degeneration (AMD). 
Methods  We reviewed retrospectively the medical records of 47 consecutive 5 
patients (47 eyes) with typical AMD who had been followed-up with IA for at least 2 
years. 
Results  At the initial visit, while all eyes showed classic and/or occult choroidal 
neovascularization (CNV) associated with AMD, no eyes showed polypoidal lesions 
by IA.  During the follow-up, however, 13 (27.7%) of the 47 eyes did show polypoidal 10 
lesions.  All polypoidal lesions developed at the edge of persistent CNV or, more 
often, at the terminus of recently progressed CNV.  Of 12 eyes with a final lesion area 
of > 8 disc area, 7 (58.3%) showed newly developed polypoidal lesions.  In eyes with 
these newly developed polypoidal lesions, the mean area of the vascular lesion had 
extended significantly from 10.50 ± 7.88 mm2 to 20.87 ± 10.21 mm2 during the 15 
follow-up (P = 0.0018). 
Conclusions  The current observation suggests that IA of active AMD sometimes 
reveals polypoidal lesions if there is progression of the CNV in the sub-retinal pigment 
epithelium space. 
 20 
Keywords:  age-related macular degeneration; indocyanine green angiography; 
polypoidal choroidal vasculopathy
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Introduction  
 
Initially, polypoidal choroidal vasculopathy (PCV) was described as a new clinical 
entity with a unique form of choroidal vascular abnormality.1-3  Since Uyama et al4, 5 
proposed that PCV is a variant of choroidal neovascularisation (CNV) in exudative 5 
age-related macular degeneration (AMD), it has been generally believed that the 
vascular components in PCV are a type of CNV, although the pathogenesis of PCV is 
not fully understood.6, 7  In general, PCV is diagnosed when polypoidal lesions are 
seen by indocyanine green angiography (IA) at the terminus of typical branching 
vascular networks.8  IA is essential for the study of the vascular lesion of PCV 10 
because most of the vascular components of PCV are located beneath the retinal 
pigment epithelium,8 so with fundus examination or fluorescein angiography (FA), it is 
often difficult to distinguish macular PCV from exudative AMD.9-11 
     An increasing number of reports have recently shown that anti-vascular 
endothelial growth factor (VEGF) therapy can reduce the exudative change and lesion 15 
size in exudative AMD, and can result in visual recovery.12-18  However, some eyes 
with exudative AMD are refractory to repeated anti-VEGF therapy.19, 20  Clinicians 
sometimes see cases of typical AMD with a large lesion that shows a poor response 
to treatment and that shows progression, which results in a poor visual prognosis.  
When we performed IA on such AMD cases with large lesions, we sometimes noted 20 
knob-like hyperfluorescent lesions at the end of progressing CNV, which resembled 
the polypoid lesions typically seen in PCV.21  Cho et al19 reported that IA revealed 
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these polypoidal lesions in 12 cases of exudative AMD with a poor response to 
anti-VEGF therapy. 
     In the clinical setting, FA is essential to make a diagnosis and to evaluate lesion 
size and its activity in exudative AMD.22  Even in exudative AMD, IA often provides 
useful information about the vascular lesions, especially those located beneath the 5 
retinal pigment epithelium.23, 24  So far, however, limited information is available using 
IA on long-term observations of the vascular components in typical AMD.  In the 
study described herein, we studied the vascular lesions of typical AMD with the use of 
IA, in order to elucidate the rate and characteristics of eyes that were initially 
diagnosed as having typical AMD and that subsequently developed polypoidal 10 
lesions. 
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Patients and methods 
 
For this observational case study, we reviewed retrospectively the medical records of 
47 consecutive patients (47 eyes) with typical AMD who initially visited the Macula 
Service, Department of Ophthalmology, Kyoto University Hospital between October 5 
2004 and October 2007 and whose eyes had been examined with both FA and IA for 
more than 2 years after the initial visit.  During this period, 116 patients with typical 
AMD initially visited our clinic.  Sixty-nine patients were excluded from the current 
study because of a short follow-up period or because they lacked FA or IA during the 
more than 2 years since the initial visit.  When both eyes showed typical AMD, only 10 
one eye was selected randomly for inclusion in the current study.  This study was 
approved by the Institutional Review Board at Kyoto University Graduate School of 
Medicine and adhered to the tenets of the Declaration of Helsinki. 
     The diagnosis of typical AMD was based on fundus photographs, FA, IA and 
optical coherence tomography (OCT), which showed type 1 and/or type 2 CNV.  15 
Eyes with other macular abnormalities (i.e., PCV, retinal angiomatous proliferation, 
pathologic myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks, 
and other secondary CNV) were excluded from the current study.  When 
reddish-orange nodules were seen by ophthalmoscopic examination or polypoidal 
lesions were seen by IA, the eye was excluded from the current study.  Eyes that had 20 
been treated previously with focal laser photocoagulation, photodynamic therapy, 
vitrectomy, radiation therapy, or anti-VEGF therapy were also excluded from the 
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present study. 
     At the initial visit, all patients had undergone a comprehensive ophthalmologic 
examination, including measurement of best-corrected visual acuity (VA), 
determination of intraocular pressure, indirect ophthalmoscopy, slitlamp 
biomicroscopy with a contact lens, and OCT.  After fundus photographs were taken, 5 
FA and IA were performed on each patient using a confocal laser scanning system 
(HRA-2, Heidelberg Engineering, Dossenheim, Germany).  VA measurement and 
OCT examination were performed on each patient at each follow-up visit; FA and IA 
were performed if necessary, and all patients in the current study were examined with 
both FA and IA several times during their follow-up. 10 
     In this study, greatest linear dimension (GLD) and area of the lesion were 
determined based on the IA with software that was built into the HRA-2.  GLD was 
defined as covering the entire CNV lesion, including type-1 and type-2 CNV, 
polypoidal lesions, and the branching vascular network.  Area of the CNV lesion was 
measured manually with software in the HRA-2.  The pigment epithelial detachment, 15 
without underlying CNV, was not included in measurement of the GLD or in area of the 
lesion.  In the current study, one optic disc area (DA) is considered to be 2.54 mm2 
on the basis of one optic disc diameter being 1.8 mm. 
     Using OCT images, we performed two measurements with a caliper that was 
built into the software of the OCT machine; using these calipers, foveal thickness and 20 
thickness of the neurosensory retina in the fovea were measured.  Foveal thickness 
was defined as the distance between the vitreoretinal interface and the retinal pigment 
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epithelium; thickness of the neurosensory retina was defined as the distance between 
the vitreoretinal interface and the tip of the outer portion of the inner and outer 
segments of the photoreceptors. 
     In the current study, measurement values obtained at the initial visit were 
compared with those obtained at the final examination.  To evaluate progression of 5 
the vascular lesions, the initial area of the CNV lesion and of the GLD were compared 
with final values.  To evaluate activity of the disease, we also compared the initial 
OCT measurement (foveal thickness and thickness of the neurosensory retina) with 
values obtained at the final visit.  To compare the difference in VA, vision as 
measured with a Landolt chart was converted to a logarithm of the minimal angle of 10 
resolution (logMAR). 
     Statistical analysis was performed using software designed for this purpose 
(StatView, version 5.0; SAS Institute, Cary, North Carolina, USA).  A P value of less 
than 0.05 was considered to be statistically significant. 
15 
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Results 
 
In the current study, 47 eyes of 47 patients (36 men and 11 women) with typical AMD 
were examined; the patients ranged in age from 56 to 90 years (72.8 ± 7.5 years).  
The follow-up period ranged from 24 to 59 months (43.9 ± 10.3 months).  All patients 5 
were examined with FA and IA repeatedly during their follow-up, ranging from 2 to 10 
times (4.6 ± 1.8 times).  Table 1 shows characteristics of patients who were eligible 
for this study.  Mean baseline VA (logMAR) was 0.70 ± 0.53, and mean initial area of 
the lesion and GLD were 8.68 ± 7.75 mm2 and 3850 ± 1627 μm, respectively.  Figure 
1 shows the relationship of area of the lesion and of the GLD obtained at the initial 10 
visit and at final examination.  The initial area of the lesion (R = 0.7347, P < 0.0001) 
and initial GLD (R = 0.7349, P < 0.0001) were correlated closely with final values. 
     At the initial visit, although all eyes of the patients involved showed classic 
and/or occult CNV associated with AMD, no eyes showed polypoidal lesions by IA.  
During the follow-up period, 34 eyes were initially treated with photodynamic therapy, 15 
and 5 were initially treated with anti-VEGF therapy.  In spite of these treatments, 
however, some eyes with typical AMD showed extension of the vascular components 
with an exudative change.  The mean area of the neovascularisation increased from 
8.68 ± 7.75 mm2 to 14.28 ± 10.57 mm2 during follow-up (P < 0.0001).  Also during 
the follow-up, 13 (27.7%) of the 47 eyes showed polypoidal lesions by IA.  All of 20 
these polypoidal lesions developed either at the edge of persistent CNV (Figure 2) or, 
more often, at the terminus of the newly progressed CNV (Figures 3 and 4).  Of 12 
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eyes with a final CNV area of > 8 DA, 7 (58.3%) showed newly developed polypoidal 
lesions (Figure 1). 
     Depending on the development of polypoidal lesions, we divided our patients 
with typical AMD into two groups—those with polypoidal lesions (n = 13) and those 
without polypoidal lesions (n = 34).  Table 1 shows baseline and final measurement 5 
values of each group.  There were no significant differences in gender or age 
between these two groups (P = 0.9739 and P = 0.8913).  Furthermore, there were no 
differences in VA (P = 0.6234), area of lesion (P = 0.3262), or GLD (P = 0.3269) at the 
initial visit.  Mean area of the lesion in eyes with polypoidal lesions enlarged 
significantly from 10.50 ± 7.88 mm2 to 20.87 ± 10.21 mm2 during the follow-up (P = 10 
0.0018).  Mean GLD in eyes with polypoidal lesions also progressed significantly 
from 4231 ± 1692 µm to 5880 ± 1947 µm (P = 0.0032).  Although mean area of the 
lesion and GLD were increased in eyes without polypoidal lesions, the increases were 
significantly greater in eyes that developed polypoidal lesions (P = 0.0036 and P = 
0.0035).  In eyes with polypoidal lesions, however, final VA was not statistically 15 
different compared with that in eyes without polypoidal lesions (P = 0.2303).   
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Discussion 
 
PCV was first described as a new clinical entity with an associated unique form of 
choroidal vascular abnormality.1-3  Subsequently, however, based on histologic 
specimens and OCT examinations, PCV is thought to be a unique form of CNV.25, 26  5 
In general, presumed exudative AMD is diagnosed as PCV when IA shows polypoidal 
lesions at the terminus of the branching vascular network.8  In PCV, IA is essential to 
make the diagnosis and to evaluate precisely the entire vascular lesion.8  In the 
current study, polypoidal lesions developed in 27.7% of eyes with typical AMD—eyes 
that had shown no polypoidal lesions at the initial visit.  All polypoidal lesions 10 
developed at the edge of persistent CNV or, more often, at the terminus of recently 
progressed CNV.  The current observation suggests that active AMD may show 
polypoidal lesions, if there is progression in the sub-retinal pigment epithelium space. 
     The tip of the extending CNV, which is the most active lesion, typically shows 
vigorous leakage on FA.22  Even if the CNV is located beneath the retinal pigment 15 
epithelium, it sometimes shows a ‘classic’ appearance, as proposed in the updated 
clinicopathologic classification of subretinal neovascularisation by Gass.27  Because 
molecules of indocyanine green readily attach to serum albumin,28 vigorous leakage is 
not seen usually by IA, even from active CNV,23, 24, 29 but CNV that is stained by 
indocyanine green may well appear as knobbed hyperfluorescent spots on IA.30  In 20 
our patients, the tips of progressive CNV associated with AMD that showed focal 
hyperfluorescence on IA might appear to be polypoidal lesions. 
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     Another interpretation is also possible.  We can assume that the branching 
vascular network and polypoidal lesions represent a variant of type-1 CNV associated 
with exudative AMD.4, 5  In the clinical setting, when no polypoidal lesions are seen, it 
is difficult to distinguish the branching vascular network from the type-1 CNV that may 
be associated with AMD.31  Clinically, some polypoidal lesions do regress 5 
spontaneously or, more commonly, after photodynamic therapy, but they tend to recur 
at the same location or at other terminals of the branching vascular network.6, 9, 32  In 
the current study, a diagnosis of typical AMD was made in all eyes, based on the initial 
IA.  It is possible that some of our patients actually had PCV which was 
misdiagnosed, and that some showed polypoidal lesions during the follow-up.  10 
Recently, Maruko et al33 reported that among 349 patients with neovascular AMD, 20 
(5.7%) had one eye with PCV while the fellow eye showed typical AMD, but that PCV 
developed during the follow-up in ten eyes that had typical AMD at the initial 
examination.  Because their patients had PCV lesions in the fellow eye, it is 
reasonable to assume that these eyes originally had PCV but did not meet the 15 
diagnostic criteria of PCV.33 
     Our patients had been examined with both FA and IA for more than 2 years after 
the initial visit.  In the current study, the rate of those eyes that were refractory to 
treatment or that showed a recurrence of CNV after the successful initial treatment 
might be relatively high.  Recently, Cho et al19 reported that polypoidal lesions were 20 
detected in 12 cases of exudative AMD with a poor response to anti-VEGF therapy.  
In their report, treatment with photodynamic therapy, photodynamic 
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therapy/anti-VEGF combination therapy, or continued anti-VEGF monotherapy 
resulted in complete resolution of exudation in 9 of 12 eyes.  In the current study, we 
showed that typical AMD refractory to treatment sometimes developed polypoidal 
lesions at the terminus of the newly progressed CNV.  However, visual prognosis of 
these eyes was not poor.  We treated eyes with polypoidal lesions primarily by 5 
photodynamic therapy or photodynamic therapy combined with ant-VEGF therapy.  
Today, anti-VEGF therapy is a primary treatment for typical AMD.  In eyes with 
exudative AMD refractory to treatment, however, we suggest that clinicians should 
reconsider the treatment strategy after re-evaluation of the CNV by IA. 
     It is still controversial as to whether PCV is a distinct clinical entity or is simply a 10 
unique form of exudative AMD.6  In Asian populations, a number of reports have 
shown that genetic variations in ARMS2 and CFH are associated strongly with both 
AMD and PCV.34-38  In addition, Lima et al39 recently reported that the PCV 
phenotype in Caucasian patients is associated with the three major AMD-associated 
loci, including CFH, ARMS2, and CFB/C2 genes, and they suggested that PCV and 15 
AMD are genetically similar in these tested loci.39  While Kondo et al40 have 
implicated the elastin gene as a susceptibility gene for PCV, it is generally thought that 
PCV and AMD share common genetic backgrounds, even though complications, 
treatment effect, and visual prognosis are somewhat different.6, 11  Indeed, PCV is a 
distinct clinical entity,9 although some advanced AMD cases do show features 20 
characteristic of PCV.33 
     Limitations of the current study are its retrospective nature and the various 
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treatment regimens used.  In the current study, active AMD sometimes showed 
polypoidal lesions at the terminus of the vascular lesion, when the neovascularisation 
showed progression in the sub-retinal pigment epithelium space.  In the clinical 
setting, eyes with a small PCV lesion often maintain good VA for a protracted period of 
time.41, 42  In contrast, cases of PCV with a large lesion that has a poor response to 5 
treatment and that shows progression, tend to have a poor visual prognosis.21  Our 
findings suggest that advanced AMD overlaps with PCV—at least with PCV that has a 
large vascular lesion. 
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Figure legends 
 
Figure 1  (a) Correlation between initial and final areas of the lesion in eyes with 
typical age-related macular degeneration.  Initial areas are correlated significantly 
with final areas of the lesion (R = 0.7347, P < 0.0001).  (b) Correlation between initial 5 
and final greatest linear dimension (GLD) in eyes with typical age-related macular 
degeneration.  Initial GLD is correlated significantly with final GLD (R = 0.7349, P < 
0.0001).  One disc area (DA) is estimated to be 2.54 mm2 on the basis of one optic 
disc diameter being 1.8 mm.  Open diamonds represent eyes without polypoidal 
lesions and closed diamonds represent eyes with polypoidal lesions. 10 
 
Figure 2  Development of polypoidal lesions at the border of persistent choroidal 
neovascularization (CNV) in a right eye with typical age-related macular degeneration.  
(a) Fundus photograph at the initial visit shows a multi-lobed serous pigment epithelial 
detachment (PED).  Visual acuity was 0.8 in this eye.  (b) Fluorescein angiography 15 
(FA) at the initial visit shows only hyperfluorescent areas associated with the PED.  
(c) Indocyanine green angiography (IA) shows CNV (arrow) at the edge of the PED; 
no polypoidal lesions are seen.  (d) Fundus photograph at 34 months after the initial 
visit.  With two photodynamic treatments, activity of the CNV has regressed.  Visual 
acuity was now 0.2 in the right eye.  (e) At 50 months after the initial visit, new 20 
serosanguineous PEDs (arrows) have developed at the upper side and 
inferotemporal side of the subfoveal disciform scar.  (f) IA shows multiple polypoidal 
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lesions (arrows) at the edge of the persistent CNV.  Visual acuity was 0.1 in this eye. 
 
Figure 3  Development of polypoidal lesions at the terminus of newly progressed 
choroidal neovascularization (CNV) in a left eye with typical age-related macular 
degeneration.  (a) Fundus photograph at the initial visit; at which time visual acuity in 5 
this eye was 1.2.  (b) Fluorescein angiography (FA) at the initial visit shows inactive 
occult CNV.  (c) Indocyanine green angiography (IA) shows no polypoidal lesions.  
(d) At 34 months after the initial visit, visual acuity had decreased to 0.15.  Fundus 
photograph shows an active exudative change at the temporal side of a subfoveal 
disciform scar.  (e) FA shows large subfoveal classic CNV with temporal active 10 
leakage from the CNV (arrow).  (f) IA shows mature subfoveal CNV (long arrow).  
The CNV has progressed temporally and now forms multiple terminal bulbs, which are 
seen as polypoidal lesions (arrow).  Three intravitreal injections of bevacizumab 
caused activity of the CNV to regress.  (g) At 64 months after the initial visit, a new 
active lesion has developed on the upper border of the subfoveal disciform scar.  15 
Visual acuity, however, remained at 0.15.  (h) FA shows newly developed CNV 
(arrow).  (i) IA shows what are presumed to be newly developed polypoidal lesions 
(arrow). 
 
Figure 4  Development of polypoidal lesions at the terminus of recently progressive 20 
choroidal neovascularization (CNV) in a right eye with typical age-related macular 
degeneration.  (a) Fundus photograph at the initial visit shows atrophy of the retinal 
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pigment epithelium.  Visual acuity was 0.4 in the right eye.  (b) Fluorescein 
angiography (FA) at the initial visit shows subfoveal occult CNV.  (c) Indocyanine 
green angiography (IA) shows CNV beneath the fovea, but no polypoidal lesions are 
seen.  With photodynamic therapy, activity of the CNV regressed.  (d) At 24 months 
after the initial visit, a new active lesion has developed at the temporal side of the 5 
regressed CNV.  Visual acuity at this time was 0.4 in the right eye.  (e) IA reveals 
multiple polypoidal lesions (arrows) at the edge of the progressive CNV.  (f) 










(n = 47) 
Polypoidal 
 lesion (+) 
 (n = 13) 
Polypoidal 
lesion (-) 




Gender (women/men) 11/36 3/10 8/26 0.9739 
Age (years) 72.8 ± 7.5 73.1 ± 5.0 72.8 ± 7.5 0.8913 
Initial conditions     
    FA findings (predominantly 









    Best-corrected VA (logMAR) 0.70 ± 0.53 0.64 ± 0.53 0.72 ± 0.53 0.6234 
    Area of lesion (mm2) 8.68 ± 7.75 10.50 ± 7.88 7.99 ± 7.75 0.3262 
    GLD (µm) 3850 ± 1627 4231 ± 1692 3705 ± 1627 0.3269 
    Foveal thickness (µm) 523.8 ± 288.6 567.5 ± 427.9 507.1 ± 288.6 0.5269 
Thickness of nerurosensory 
retina in the fovea (µm) 
284.8 ± 199.5 314.2 ± 317.6 273.6 ± 199.5 0.5388 
     
Follow-up duration (months) 43.9 ± 10.3 47.4 ± 9.1 42.5 ± 10.3 0.1481 
Treatment     
    Photodynamic therapy 35 8 27 0.2087 
        (number of treatments) 2.0 ± 1.1 2.4 ± 1.4 1.9 ± 1.1 0.3044 
    Anti-VEGF therapy 21 5 16 0.5959 
        (number of treatments) 3.1 ± 4.1 3.0 ± 2.9 3.2 ± 4.1 0.9322 
     
Final conditions     
    Best-corrected VA (logMAR) 0.89 ± 0.50 0.74 ± 0.40 0.94 ± 0.50 0.2303 
    Area of lesion (mm2) 14.28 ± 10.57 20.87 ± 10.21 11.77 ± 10.57 0.0068 
    GLD (µm) 4628 ± 1893 5880 ± 1947 4149 ± 1893 0.0039 
    Foveal thickness (µm) 449.4 ± 352.8 467.7 ± 334.0 442.5 ± 352.8 0.8292 
Thickness of nerurosensory 
retina in the fovea (µm) 
245.0 ± 236.9 194.3 ± 127.6 264.4 ± 236.9 0.3700 
     
Changes during follow-up     
    Best-corrected VA (logMAR) 0.19 ± 0.45 0.11 ± 0.52 0.22 ± 0.45 0.4470 
    Area of lesion (mm2) 5.60 ± 7.17 10.38 ± 9.35 3.78 ± 7.17 0.0036 
    GLD (µm) 777 ± 1306 1649 ± 1623 444 ± 1306 0.0035 
    Foveal thickness (µm) -76.8 ± 364.6 -111.3 ± 463.5 -64.6 ± 364.6 0.7076 
Thickness of nerurosensory 
retina in the fovea (µm) 
-38.5 ± 284.7 -121.7 ± 328.1 -9.2 ± 284.7 0.2437 
FA = fluorescein angiography; n = number; VA = visual acuity; logMAR=logarithm of the minimum angle of 
resolution; GLD = greatest linear dimension of the entire lesion; VEGF = vascular endothelial growth factor.  
